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Mutations in the Novel Mitochondrial Protein REEP1 Cause
Hereditary Spastic Paraplegia Type 31
Stephan Zu¨chner, Gaofeng Wang, Khanh-Nhat Tran-Viet, Martha A. Nance, Perry C. Gaskell,
Jeffery M. Vance, Allison E. Ashley-Koch, and Margaret A. Pericak-Vance
Hereditary spastic paraplegia (HSP) comprises a group of clinically and genetically heterogeneous diseases that affect the
upper motor neurons and their axonal projections. For the novel SPG31 locus on chromosome 2p12, we identiﬁed six
different mutations in the receptor expression–enhancing protein 1 gene (REEP1). REEP1 mutations occurred in 6.5% of
the patients with HSP in our sample, making it the third-most common HSP gene. We show that REEP1 is widely
expressed and localizes to mitochondria, which underlines the importance of mitochondrial function in neurodegen-
erative disease.
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In hereditary spastic paraplegia (HSP), the degeneration
of corticospinal tract axons leads to progressive lower-limb
spastic paralysis. Traditionally, HSP types have been di-
vided into pure and complicated forms, which are char-
acterized by additional symptoms such as mental retar-
dation, epilepsy, cerebellar ataxia, or optic atrophy.1 Ge-
netic studies have revealed as many as 31 different chro-
mosomal HSP loci. Five genes have been identiﬁed for
autosomal dominant subtypes.2 Mutations in the genes
spastin (SPG4) and atlastin (SPG3A) account for up to 50%
of all HSP cases. Mutations in KIF5A (MIM 602821),HSP60
(MIM 118190), and NIPA1 (MIM 608145) each occur in
!1% of HSP cases.3,4
Elsewhere, we performed a genomewide linkage study
and identiﬁed a “pure” HSP locus at chromosome 2p12
(SPG31).5 Two families, DUK2036 and DUK2299, yielded
a combined two-point LOD score of 4.7 atmarkerD2S2951.
Fine-mapping and haplotype analysis narrowed the locus
to ∼8.8 Mb between D2S139 and D2S2181 (ﬁg. 1A). We
chose nine candidate genes (CTNNA2, SUCLG1, TGOLN2,
MATA2A, VAMP8, VAMP5, IMMT, VPS24, and REEP1 [MIM
609139]) on the basis of emerging pathways for spastic
paraplegia and conserved protein domains contained in
proteins that cause neurodegenerative diseases.6 Of those
genes, we sequenced all exons, including 40 bp of ﬂank-
ing intronic and UTR sequences. We identiﬁed a single
base-pair deletion, c.507delC, in family DUK2299 and a
splice-site mutation, c.182-2ArG, in family DUK2036 in
the receptor expression–enhancing protein 1 gene (REEP1),
also known as “C2orf23” (ﬁg. 1B and 1C). These sequence
changes resulted in frameshifts leading to altered stop co-
dons. The mutations cosegregated with the disorder in the
linked pedigrees (ﬁg. 2). REEP1 (GenBank accession num-
ber NP_075063) belongs to a novel protein family that
was identiﬁed only recently.7 Its subcellular location and
molecular function are largely unknown. We screened
for additional REEP1 mutations in a sample of 90 inde-
pendent HSP-affected families of European descent, nei-
ther selected for pure HSP phenotype nor tested for mu-
tations in other HSP genes. All individuals were studied
under internal review board–approved procedures. We
identiﬁed four more mutations that led to signiﬁcant
sequence changes in REEP1: one missense mutation
(c.59CrA; Ala20Glu), one deletion (c.526delG; Gly176fs),
and two 3′ UTR changes (c.60643GrTandc.60650GrA)
(ﬁg. 1B and 1C and table 1). All mutations cosegregated
with the HSP phenotype in the available pedigrees and
were undetected in 365 control individuals of European
descent (730 chromosomes) (ﬁg. 2).
The splice-site mutation in linked family DUK2036 dis-
rupted the canonical 5′ acceptor splicing signal “AG” of
exon 4 (ﬁg. 1B and 1C). REEP1 was not expressed in pe-
ripheral-blood cells, and neuronal tissue was not available
from affected family members (ﬁg. 3K). Thus, we could not
demonstrate the aberrantmRNA (GenBank accession num-
ber NM_022912), but simulation of the resulting splice
efﬁciency with NNSPLICE revealed a reduction from 99%
efﬁciency of the wild-type AG allele to 0% of the mutant
GG allele. Missplicing of exon 4 will result in a frameshift
followed by a premature stop codon. The two mutations
in the 3′ UTR presented unusual changes for a Mendelian
disease. However, both mutations altered the sequence
of a predicted highly conserved binding site for the mi-
croRNA (miRNA) gene miR-140 (ﬁg. 1D and 1E). miRNAs
constitute a new large class of small noncoding RNA genes
that target protein-coding genes for posttranscriptional re-
pression8 (see the MicroRNA Registry). The c.60643GrT
mutation in REEP1 disrupted a G:U wobble base pair, and
the c.60650GrA change replaced aG:Uwobble base pair
with an A:U Watson-Crick pairing. It has been shown that
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Figure 1. Overview of the SPG31 locus and identiﬁed genetic variation in REEP1. A, Within the minimal chromosomal SPG31 region,
we screened several genes by direct sequencing analysis. B, REEP1 consists of seven exons (black boxes) and contains two predicted
transmembrane domains (TM1 and TM2) and a “deleted in polyposis” domain (TB2/DP1/HVA22). The 3′ UTR comprises a conserved
miRNA target site for miR-140 (MT). C, Sequencing traces of the identiﬁed unique mutations in six families with uncomplicated HSP.
Sequencing analysis was performed using an ABI3730, following standard procedures. PCR primers are available from the authors on
request. D, The miR-140 target site in the 3′ UTR is highly conserved. Two mutations within that site change nucleotides that provide
G:U wobble base pairing: c.60643GrU and c.60650GrA (gray shading, blue letters, and arrows). E, The mature miR-140 gene is
also highly conserved, including the two residues that would bind to the mutated nucleotides in the target site (gray shading and
arrows). cen p centromere; tel p telomere.
Figure 2. Different mutations identiﬁed in six unrelated HSP-af-
fected families: DUK2369, DUK2354, DUK1959, DUK2036, DUK2189,
and DUK2299. The legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
G:U wobble base pairing has an inhibitory effect on mi-
RNA-mediated repression of translation.9 Thus, both de-
tected mutations would foster suppressive miRNA-medi-
ated effects on translation, leading to less available REEP1
protein. Both affected nucleotides are highly conserved in
the REEP1 3′ UTR as well as in miR-140 of different species
(ﬁg. 1D and 1E). In addition, it has been shown that miR-
140 is expressed in the cortex of rat and monkey as well
as in cultured primary cortical neurons from rat.10,11 Thus,
we suggest that the identiﬁed sequence variants will affect
the amount of translated REEP1 in patients with HSP.
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Table 1. Clinical and Genetic Features of the
Identiﬁed Families with REEP1 Mutations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3. REEP1 localized to mitochondria. A–F, Immunohistochemistry with two different REEP1 antibodies revealed colocalization
with the marker Mitotracker Red. COS7 (kidney) and MN-1 (motor neuron) cells were maintained in Dulbecco’s modiﬁed Eagle medium
with 10% fetal bovine serum and were incubated at 37C supplemented with 5% CO2. Cells were observed by confocal laser scan mi-
croscopy (Visitech model VT-Inﬁnity). G and H, No colocalization was observed with microtubules and Golgi. I, COS7 cells were ho-
mogenized and mitochondria were separated from the cytosolic fraction by centrifugation. The REEP1 antibodies were probed against
COS7 cell lysate on a western blot and showed a band of the expected size in the mitochondrial fraction. The blot was reprobed with
porin, which constitutes a mitochondrial membrane protein, and b-actin. Note that the cytosolic fraction was highly enriched, as shown
by the b-actin bands. J, RT-PCR on a series of tissues revealed ubiquitous expression. REEP1 was not expressed in peripheral blood and
ﬁbroblasts derived from a skin biopsy.
Three of the four coding changes led to alternative stop
codons. It is likely that the resultingmRNAwill be targeted
for nonsense-mediated decay, resulting in haploinsufﬁ-
ciency of the mutant allele. Interestingly, both miRNA
target-site mutations disrupted G:U base pairing and are
therefore likely to lead to less translated protein. We sug-
gest that loss of function and haploinsufﬁciency are the
mechanisms of action in REEP1-related spastic paraplegia.
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Figure 4. Antibody design for REEP1. The legend is available in
its entirety in the online edition of The American Journal of Human
Genetics.
Figure 5. REEP1 is highly conserved throughout different spe-
cies. The legend is available in its entirety in the online edition
of The American Journal of Human Genetics.
As shown by Saito et al.7 and extended in the present
study, REEP1 is expressed in various nonneuronal andneu-
ronal tissues, including spinal cord (ﬁg. 3K). This follows
the now-common ﬁnding of almost ubiquitous tissue ex-
pression for a number of genes that cause distinct neuro-
degenerative phenotypes. Saito et al. showed that REEP1
has a weak promoting effect on the expression of G pro-
tein–coupled odorant-receptor proteins at the cell surface.7
Thus, REEP1 might have a role in trafﬁcking of odorant
receptors and other molecules through cellular compart-
ments such as the endoplasmic reticulum and Golgi ap-
paratus. The yeast homologue of REEP1, Yop1P, is involved
in Rab-mediated vesicle transport, a pathway that has re-
cently been implicated in axonal neuropathy type CMT2B,
which is caused by mutations in RAB7.12,13 In silico analysis
of REEP1 predicted two transmembrane domains and the
conserved protein domain TB2/DP1/HVA22 (ﬁg. 1B). As
shown by Chen et al., the plant homologues of HVA22
are stress-induced genes—a characteristic known fromheat-
shock proteins.14 Heat-shock proteins play a fundamental
role as chaperones to promote and maintain correct pro-
tein folding, especially in cell compartments rich in re-
active oxygen species, such as mitochondria. Mutations
in the mitochondrial heat-shock protein 60 have been
shown to cause spastic paraplegia type SPG13.4 It has also
been suggested that the spastic paraplegia gene paraplegin
(SPG7 [MIM 602781]) fulﬁlls chaperonelike activities in
mitochondria.15
We designed two speciﬁc polyclonal antibodies that tar-
geted the C terminal of REEP1 (ﬁg. 4). Staining of COS7
and MN-1 cells with those antibodies revealed that en-
dogenous REEP1 colocalized with mitochondria (ﬁg. 3A–
3F). REEP1 was also present in the mitochondrial but not
the cytosolic cellular fraction on an immunoblot (ﬁg. 3I).
Given the predicted transmembrane domains (ﬁgs. 1B and
5), we suggest that REEP1 is a novel mitochondrial mem-
brane protein.
Although the results of Saito et al. suggested localization
of REEP1 to the secretory pathway,7 we did not detect
colocalization of REEP1 with the Golgi (ﬁg. 1H). It is con-
ceivable that REEP1 has different cellular functions and
that a fraction of the protein, which was not detectable
with the available antibodies, indeed fulﬁlls functions in
the endoplasmic reticulum and Golgi. In support of this
hypothesis, the ENSEMBL human genome database lists
two alternative isoforms of REEP1 that might represent
such differential functionality. However, we were not able
to unequivocally reproduce the existence of this second
isoform.
Although the speciﬁc function of REEP1 in mitochon-
dria has not been elucidated, this ﬁnding contributes fur-
ther to the evidence that mitochondrial integrity takes cen-
ter stage in HSP and related neurodegenerative diseases.6
In summary, we have identiﬁed the gene for the SPG31
locus, REEP1, which accounted, in our sample, for 6.5% of
all HSP cases. We have demonstrated that REEP1 is local-
ized to mitochondria, and, derived from its conserved pro-
tein-domain structure, REEP1 might be involved in chap-
eronelike activities.
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Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
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